Figure 4 from PARP Inhibitors Differentially Regulate Immune Responses in Distinct Genetic Backgrounds of High-Grade Serous Tubo-Ovarian Carcinoma

Talazoparib treatment upregulates CXCL10 gene expression in three, BRCA wild-type HGSC cell lines compared with veliparib treatment. A and D, OVCAR3, (B and E) OVCAR4 cells, and (C and F) CAOV3 cells were treated with a vehicle control (DMSO) or 10 μmol/L Veliparib or 2 μmol/L Talazoparib. Cell pellets and supernatants were collected 48 hours after drug treatment. A–C, Two micrograms of total RNA extracted from cell pellets was reverse transcribed to cDNA and then analyzed by qRT-PCR for CXCL10 and GAPDH expression. D–F, Supernatants were tested for CXCL10 (IP-10) protein levels using an ELISA assay. A five-parameter logistic curve fit was used to analyze these results. *, P < 0.05; **, P < 0.01; ns, not statistically significant.